Iodixanol

Summary

Iodixanol (CHEMBL1200507) is an approved unknown radioopaque medium (ATC V08AB09); indicated across 1 condition including acute kidney injury.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Unknown
• ATC class: V08AB09
• Indications: 1 condition
• Clinical trials: 34
• Chemistry: 1550.2 Da · C35H44I6N6O15

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1200507
Name	Iodixanol
Type	Unknown
Max phase	4
FDA approved	yes
PubChem CID	3724
ChEBI	CHEBI:31705
ATC	V08AB09
Molecular formula	C35H44I6N6O15
Molecular weight	1550.2
InChIKey	NBQNWMBBSKPBAY-UHFFFAOYSA-N

SMILES: CC(=O)N(CC(CN(C1=C(C(=C(C(=C1I)C(=O)NCC(CO)O)I)C(=O)NCC(CO)O)I)C(=O)C)O)C2=C(C(=C(C(=C2I)C(=O)NCC(CO)O)I)C(=O)NCC(CO)O)I

IUPAC name: 5-[acetyl-[3-[N-acetyl-3,5-bis(2,3-dihydroxypropylcarbamoyl)-2,4,6-triiodoanilino]-2-hydroxypropyl]amino]-1-N,3-N-bis(2,3-dihydroxypropyl)-2,4,6-triiodobenzene-1,3-dicarboxamide

ChEBI definition: A dimeric, non-ionic, water-soluble, radiographic contrast agent, used particularly in coronary angiography.

Pharmacological roles (ChEBI): radioopaque medium.

Also known as: Iodixanol, NSC-760069, Visipaque, Visipaque 270, Visipaque 320, IODIXANOL, iodixanol, SID144204262, SID170464924

Patent coverage: 5,478 distinct patent families (16,994 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
acute kidney injury	0	MONDO:0002492	HP:0001919

Clinical trials

Total trials: 34.

Phase distribution

Phase	Trials
PHASE4	21
Not specified	7
PHASE3	4
EARLY_PHASE1	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00209417	PHASE4	TERMINATED	Renal Effects of Two Iodinated Contrast Media in Patients at Risk Undergoing Computed Tomography
NCT00209430	PHASE4	COMPLETED	Renal Effects of Two Iodinated Contrast Media in Patients at Risk Undergoing Coronary Angiography
NCT00335101	PHASE4	WITHDRAWN	Renal Effects of Three Iodinated Contrast Media (CM) in Patients at Risk Undergoing Coronary Angiography
NCT00347022	PHASE4	COMPLETED	A Clinical Study of Xenetix 300 in Multislice Computed Tomography (CT) Pediatric Indications
NCT00390585	PHASE4	COMPLETED	Iodixanol vs. Iomeprol to Prevent Contrast-Induced Nephropathy After Coronary Intervention (CONTRAST)
NCT00558142	PHASE4	COMPLETED	Mechanisms for the Effect of Acetylcysteine on Renal Function After Exposure to Radiographic Contrast Material
NCT00740207	PHASE4	COMPLETED	Pilot Study to Compare ISOVUE®-250 and VISIPAQUE™ 270 for Motion Artifact and Pain in Peripheral DSA
NCT00782639	PHASE4	TERMINATED	Renal Safety of Iopamidol Versus Iodixanol During Coronary Angiography in Diabetic Patients
NCT00793182	PHASE4	TERMINATED	Effects of Contrast Media on Subjects With Stable Reduced Renal Function Undergoing Contrast-Enhanced Computed Tomography
NCT00827788	PHASE4	COMPLETED	Comparison Between Iso-Osmolar and Ipo-Osmolar Contrast Agents in Patients With Acute Myocardial Infarction (AMI) Undergoing Primary Percutaneous Coronary Intervention (PCI)
NCT00926562	PHASE4	COMPLETED	A Safety Comparison of Iopromide and Iodixanol in Renal Impaired Patients
NCT01075217	PHASE4	COMPLETED	Isovue in Peripheral Digital Subtraction Angiography (DSA)
NCT01136915	PHASE4	TERMINATED	Kidney Damage In Patients With Severe Fall In eGFR
NCT01376089	PHASE4	COMPLETED	Iodixanol Versus Iopamidol in Patients Undergoing Contrast-Enhanced Computed Tomographic Imaging of Abdomen/Pelvis
NCT01402219	PHASE4	TERMINATED	Nephrotoxicity of Iopamidol Versus Iodixanol in High-Risk Patients
NCT01475097	PHASE4	COMPLETED	Comparing Patient Comfort and Safety Between Iodixanol and Iopamidol in Patients Undergoing Peripheral Arteriography
NCT01580046	PHASE4	UNKNOWN	Renal Toxicity of Iodixanol and Iopromide in Patients With Renal Dysfunction
NCT01848899	PHASE4	COMPLETED	Effects Contrast on Platelet Activity, Thrombosis and Fibrinolysis in Patients Undergoing Coronary Angiography
NCT03119662	PHASE4	TERMINATED	A Study to Explore the Renal Safety of Visipaque Injection 320 mgI/mL in Patients With Chronic Kidney Disease
NCT03631771	PHASE4	WITHDRAWN	Pediatric Risk of Hypothyroidism With Iodinated Contrast Media
NCT05065073	PHASE4	UNKNOWN	Iso-Osmolar vs. Low-Osmolar Contrast Agents for Optical Coherence Tomography
NCT00335335	PHASE3	TERMINATED	Safety and Effectiveness of Visipaque 320mg-I/ml for Use in Contrast-Enhanced CT Angiography of Arteries of the Heart
NCT00348608	PHASE3	TERMINATED	Safety and Effectiveness of Visipaque 320mg-I/ml for Use in Contrast-Enhanced CT Angiography of Arteries of the Heart
NCT02171247	PHASE3	COMPLETED	Comparison of Isovue 370 vs. Standard Protocol in Coronary Computed Tomographic Angiography (CTA)
NCT03333330	PHASE3	COMPLETED	IMaging Della PLAcca Carotidea
NCT05490381	PHASE1	WITHDRAWN	Preoperative Embolization of Hypervascular Head and Neck Tumors to Improve Surgical Outcomes
NCT01908309	EARLY_PHASE1	COMPLETED	Contrast-inDuced nephRotoxicity as Assessed by the KIdney Load-to-DAmage RElationship
NCT01146639	Not specified	COMPLETED	DynaCT in Preoperative Imaging Before Insertion of Stentgraft
NCT01188486	Not specified	TERMINATED	Pulmonary Interstitial Lymphography in Early Stage Lung Cancer
NCT01326364	Not specified	TERMINATED	Prognostic Value of Baseline Computed Tomography (CT) Perfusion Parameters of Pancreatic Cancer for Patients Undergoing Stereotactic Body Radiotherapy or Surgical Resection
NCT01935141	Not specified	WITHDRAWN	Efficacy of Low (30ml) Versus Full Dose (100ml) Contrast CT Pulmonary Angiography in Detecting Emboli
NCT02405377	Not specified	COMPLETED	Central Venous Pressure Guided Hydration Prevention for Contrast-Induced Nephropathy
NCT02718521	Not specified	UNKNOWN	Adequate Hydration Therapy Combined With Intravenous Infusion of Isosorbide Dinitrate Prevention for CIN
NCT03671603	Not specified	COMPLETED	Post-Marketing Safety Study in ST-Segment Elevation Myocardial Infarction (STEMI) Participants Undergoing Primary Percutaneous Coronary Intervention (PCI) Procedure With VISIPAQUE® as the Contrast Medium

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).